Wednesday, April 4, 2012
Human Genome Sciences Inc., of Rockville, Md., said partner GlaxoSmithKline plc, of London, announced top-line results from seven of eight Phase III (Harmony) trials of albiglutide for Type II diabetes showing positive results. Harmony 6 compared albiglutide to preprandial insulin, finding clinically significant reductions in HbA1c. Harmony 7 results, comparing albiglutide to once-a-day liraglutide, were announced in November 2011. For ongoing Harmony 1 through 5 trials, early study data showed results consistent with the two completed studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.